RJFSA
APGE icon

Raymond James Financial Services Advisors’s Apogee Therapeutics APGE Stock Holding History

Raymond James Financial Services Advisors’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,874
Closed -$324K – 3405
2024
Q1 		$324K Buy
+4,874
New +$213K ﹤0.01% 2793

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raymond James Financial Services Advisors's APGE Position: Q2 2024 in Review

Raymond James Financial Services Advisors sold out of Apogee Therapeutics (APGE) in Q2 2024, closing a stake of 4,874 shares — an estimated $324K sold.

Raymond James Financial Services Advisors first reported a position in APGE in Q1 2024 and held it in 1 quarter. The position peaked at $324K in Q1 2024. 139 funds tracked by Wall St. Rank hold APGE as of Q2 2024.

  • Raymond James Financial Services Advisors reported no remaining Apogee Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 4,874 Apogee Therapeutics shares in Q2 2024, an estimated $324K.
  • Raymond James Financial Services Advisors first reported a position in Apogee Therapeutics in Q1 2024 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Apogee Therapeutics position peaked at $324K in Q1 2024.
  • 139 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2024, filed 19 Jul 2024.